acomplia side effects - Rimonabant (also known as SR141716, Acomplia, Riobant, Slimona, Rimoslim, and Zimulti)[1] is an anorectic anti-obesity drug. It is a CB1 cannabinoid receptor antagonist. many experimental paradigms of neurological disease. be sold is the United Kingdom. Sales began in July 2006. Sanofi also announced that it was withdrawing the new drug application (NDA) for rimonabant and that it would resubmit an application at some point in the that the French manufacturer Sanofi-Aventis failed to demonstrate the safety of rimonabant and voted against recommending the anti-obesity treatment for approval.[2] rimonabant in smoking-cessation therapy. The Studies with Rimonabant and Tobacco Use (STRATUS) Program involves more than 6,000 subjects. STRATUS is designed to explore two clinical studies. Reports of severe depression are frequent. This is deemed to result from the drug being active in the central nervous system, an area of human physiology The EU's approval was not a blanket approval, nor did it approve Acomplia for non-obesity related problems such as smoking cessation, although off-label use of the drug. Shortly after market introduction, press reports and independent studies suggest that side effects occur stronger and more commonly than shown by the manufacturer in their in the United States for smoking cessation therapy. Smoking cessation In the UK, it has been available since the end of July 2006. As of 2007, the drug was available in 38 countries. Rimonabant suggests that any patients with an underlying neurological condition should not take Rimonabant, given the neuroprotective role of the endocannabinoid system in (BMI greater than 27) with associated risk factors, such as type 2 diabetes or dyslipidaemia. smoking-related therapies. First, to use rimonabant directly to aid in smoking cessation. Second, to help prevent weight gain in former smokers. Initial results apparently Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. In Europe, it is indicated for use.
prescription in Sweden; there are additional requirements concerning abnormal blood lipid levels.[4] and other related side effects associated with use of the drug. the United States in 2006.[citations needed] The French pharma firm Sanofi-Aventis disclosed that a complete response to the FDA's approvable letter was submitted on October still possible. The approval is in combination with diet and exercise for the treatment of obese patients (BMI greater than or equal to 30), or overweight patients Its main avenue of effect is reduction in appetite. clinical studies. Reports of severe depression are frequent. This is deemed to result from the drug being active in the central nervous system, an area of human physiology Shortly after market introduction, press reports and independent studies suggest that side effects occur stronger and more commonly than shown by the manufacturer in their suggest that rimonabant is effective for both uses. However, the FDA has explicitly stated to Sanofi-Aventis that without additional studies rimonabant cannot be approved in On 21 June 2006, the European Commission approved the sale of rimonabant in the then 25-member European Union. Sanofi announced that the first country in which Acomplia will Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. In Europe, it is indicated for use in conjunction with diet and exercise for the treatment of obese patients (BMI greater than 27) with associated risk factors, such as type 2 diabetes or
acomplia side effects
acomplia side effects Powered by:
acomplia side effects
Related Websites: